GARADACIMAB
Information current as at: 1 May 2025
The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- TBD
- Pharmaceutical company:
- CSL BEHRING (AUSTRALIA) PTY LTD
- Condition/indication:
(therapeutic use) -
- Hereditary angioedema (HAE)
- PBAC Submission type:
- New PBS listing (Category 1)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – November 2024
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 31/07/2024 and close 25/09/2024 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2024
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
Case ID: a938
Page last updated: 30 April 2025